Literature DB >> 24057014

EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.

Michael I Webb1, Charles J Walsby.   

Abstract

EPR (electron paramagnetic resonance) has been used to study interactions of the Ru(III) anticancer compounds imidazolium [trans-RuCl4(1H-imidazole)(DMSO-S)] (NAMI-A) and indazolium [trans-RuCl4(1H-indazole)2] (KP1019) with isolated subcellular components and whole cells of the yeast Saccharomyces cerevisiae. These studies are the first to probe the intracellular speciation of ruthenium using the EPR technique. Initially, NAMI-A and KP1019 were incubated at 30 °C, for time periods up to 24 hours with isolated cell wall, mitochondrial, cytoplasmic, and nuclear fractions of S. cerevisiae. EPR measurements demonstrate that NAMI-A initially forms non-coordinate interactions with each cell component. After longer incubation times these are replaced by coordinated species, particularly with cytoplasmic proteins. KP1019 shows a greater tendency to coordinate directly with cell components, demonstrating significant interactions with mitochondria and cytoplasmic proteins. Subsequently, each complex was incubated with whole cells of S. cerevisiae at 30 °C and whole-cell EPR measurements detected Ru(III) species in measurable concentrations even after 24 hours of incubation. Analysis of the resulting EPR spectra suggests NAMI-A interacts predominantly with cell walls, while KP1019 was found to be coordinating with both the mitochondrial and cytoplasmic protein fractions. Comparison of the signal intensity of these data with those from incubation with whole cells at 4 °C indicates different modes of transmembrane transport for each complex. These studies demonstrate that EPR can provide valuable insight into the oxidation state and speciation of ruthenium compounds in cellular environments.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24057014     DOI: 10.1039/c3mt00090g

Source DB:  PubMed          Journal:  Metallomics        ISSN: 1756-5901            Impact factor:   4.526


  6 in total

1.  Proteomic analysis of the S. cerevisiae response to the anticancer ruthenium complex KP1019.

Authors:  Laura K Stultz; Alexandra Hunsucker; Sydney Middleton; Evan Grovenstein; Jacob O'Leary; Eliot Blatt; Mary Miller; James Mobley; Pamela K Hanson
Journal:  Metallomics       Date:  2020-06-24       Impact factor: 4.526

Review 2.  Ruthenium(ii)-arene complexes as anti-metastatic agents, and related techniques.

Authors:  Chanchal Sonkar; Sayantan Sarkar; Suman Mukhopadhyay
Journal:  RSC Med Chem       Date:  2021-09-15

3.  Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.

Authors:  L Brescacin; A Masi; G Sava; A Bergamo
Journal:  J Biol Inorg Chem       Date:  2015-09-14       Impact factor: 3.358

4.  A systematic assessment of chemical, genetic, and epigenetic factors influencing the activity of anticancer drug KP1019 (FFC14A).

Authors:  Upendarrao Golla; Swati Swagatika; Sakshi Chauhan; Raghuvir Singh Tomar
Journal:  Oncotarget       Date:  2017-09-30

5.  X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism.

Authors:  Aleksandar Bijelic; Sarah Theiner; Bernhard K Keppler; Annette Rompel
Journal:  J Med Chem       Date:  2016-06-07       Impact factor: 7.446

6.  A kinetic study and mechanisms of reduction of N, N'-phenylenebis(salicyalideneiminato)cobalt(III) by L-ascorbic acid in DMSO-water medium.

Authors:  S Abdulsalam; S O Idris; G A Shallangwa; A D Onu
Journal:  Heliyon       Date:  2020-09-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.